One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Johnson & Johnson (JNJ) said that Health Canada has issued a Notice of Compliance for CARVYKTI (ciltacabtagene autoleucel) for the ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

If these were antibodies recognizing His, they would bind to all six types of HA ... Our sorted cross-reactive B cells are most likely CD38+ memory B cells, as shown in Supplementary Figure 6.

Paris: Sanofi has announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

Treatment for relapsed or refractory multiple myeloma includes anti-CD38 antibodies, immunomodulating agents, CAR-T cell therapies, and bispecific antibodies, with evolving options enhancing patient ...